LYON, France, May 17, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic ultrasound, announced today that its Ablatherm® High Intensity Focused Ultrasound (HIFU) will be featured in two presentations supporting the technology's efficacy for the treatment of localized prostate cancer, both as a primary care option and as a salvage treatment. The data, as well as EDAP's extracorporeal shock wave lithotripsy (ESWL) platform, the Sonolith® i-move, will be featured at the American Urological Association (AUA) 2012 Annual Meeting, held May 19-23 in Atlanta, GA.
